
Please try another search
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. It offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. The company’s lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the potential treatment of autoimmune diseases and relapsed/refractory B-cell non-hodgkin’s lymphoma. It also develops ADI-270, an armored gamma delta CAR T cell product candidate to treat multiple CD70+ solid tumor and hematological malignancies indications, with renal cell carcinoma. The company was founded in 2014 and is based in Boston, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Chen Schor | 53 | 2020 | CEO, President & Director |
Steve Dubin | 71 | 2020 | Independent Director |
Andrew Sinclair | 53 | 2021 | Lead Independent Director |
Marco L. Davila | - | 2021 | Member of Scientific Advisory Board |
Alice Bertaina | - | 2021 | Member of Scientific Advisory Board |
Saul Priceman | - | 2021 | Member of Scientific Advisory Board |
Jeffrey Allan Chodakewitz | 70 | 2020 | Independent Director |
Constantine Mitsiades | - | 2021 | Member of Scientific Advisory Board |
Katie Peng | 54 | 2023 | Independent Director |
Michael J. Grissinger | 72 | 2025 | Director |
Lloyd Klickstein | 68 | 2020 | Independent Director |
Michael Kalos | - | 2021 | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review